L-dopa related hyperhomocysteinemia and development of dementia in Parkinson's disease

被引：0
|
作者：
dell'Aquila, C.
Zoccolella, S.
Mascolo, L.
Abruzzese, G.
Antonini, A.
Bonuccelli, U.
Dlazio, G.
Pacchetti, C.
Lamberti, P.
机构：
来源：
MOVEMENT DISORDERS | 2008年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
760
引用
收藏
页码：S249 / S249
页数：1
相关论文
共 50 条
  • [1] Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinson's Disease: Potential Implications in Cognitive Dysfunction and Dementia?
    Zoccolella, S.
    Lamberti, S. V.
    Iliceto, G.
    Santamato, A.
    Lamberti, P.
    Logroscino, G.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (28) : 3253 - 3261
  • [2] The effects of L-Dopa on attention in Parkinson's disease and Parkinson's dementia patients
    Molloy, S
    McKeith, IG
    Burn, D
    Wesnes, KA
    JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) : A51 - A51
  • [3] The effects of L-dopa on attention in Parkinson's disease and Parkinson's dementia patients
    Molloy, S.
    McKeith, I. G.
    Burn, D.
    Wesnes, K. A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 294 - 294
  • [4] Hyperhomocysteinemia in Parkinson patients treated with L-DOPA
    Bayulkem, K
    Gurpinar, B
    Bayulkem, G
    Asantugrul, E
    Bayulkem, B
    MOVEMENT DISORDERS, 2006, 21 : S83 - S83
  • [5] Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration
    Lamberti, P
    Zoccolella, S
    Armenise, E
    Lamberti, SV
    Fraddosio, A
    de Mari, M
    IIiceto, G
    Livrea, P
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (05) : 365 - 368
  • [6] L-dopa response in Parkinson's disease - A study with L-dopa infusion test
    Saiki, H.
    Matsumoto, S.
    MOVEMENT DISORDERS, 2012, 27 : S50 - S50
  • [7] L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia
    Bonelli, SB
    Ransmayr, G
    Steffelbauer, M
    Lukas, T
    Lampl, C
    Deibl, M
    NEUROLOGY, 2004, 63 (02) : 376 - 378
  • [8] Peculiarities of L-DOPA treatment of Parkinson’s disease
    R. M. Kostrzewa
    P. Nowak
    J. P. Kostrzewa
    R. A. Kostrzewa
    R. Brus
    Amino Acids, 2005, 28 : 157 - 164
  • [9] L-dopa related hyperhomocysteinemia: A possible mediator of toxicity?
    Zoccolella, S
    Iliceto, G
    deMari, M
    Defazio, G
    Livrea, P
    Lamberti, P
    LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (07) : 558 - 562
  • [10] Monitoring of L-dopa concentrations in Parkinson's disease
    Furlanut, M
    Furlanut, M
    Benetello, P
    PHARMACOLOGICAL RESEARCH, 2001, 43 (05) : 423 - 427
12345